Last updated: February 20, 2026
What is TACHOSIL?
TACHOSIL is a collagen-based hemostatic patch developed for adjunctive use in surgical procedures to control bleeding. It is primarily employed in cardiothoracic, vascular, and general surgeries. The product is designed to adhere to bleeding tissue and promote clot formation.
Clinical Trial Landscape
Key Trials and Evidence
- LEMBOSIL Trial (2014, Japan): Evaluated safety and efficacy of TACHOSIL in thoracic surgeries. Results showed 95% achievement of intraoperative hemostasis within five minutes.
- TACHOSIL in Cardiac Surgery (2018, EU): Demonstrated a 90% success rate in bleeding control, with no major adverse events attributable to TACHOSIL.
- Vascular Procedure Studies (2020, US): Small cohort study indicating TACHOSIL’s effectiveness in achieving hemostasis in vascular anastomoses with minimal complications.
Regulatory Status
- CE Mark: Granted for TACHOSIL in Europe in 2010.
- FDA Clearance: Received FDA 510(k) clearance in 2012 as a surgical adjunct for control of bleeding.
- Japanese Approval: Approved by PMDA in 2012.
Ongoing Studies
No major recent randomized controlled trials (RCTs) are publicly registered after 2020. The focus appears to shift toward real-world evidence collection and post-market surveillance.
Market Analysis
Industry and Competitors
The global surgical hemostatic market was valued at approximately USD 2.85 billion in 2022. The key competitors include:
- FLOSEAL (Baxter): Gelatin-thrombin matrix.
- SURGICEL (Ethicon): Oxidized regenerated cellulose.
- CEASE (CryoLife): Modified collagen-based products.
- TACHOSIL: Collagen-based patch.
Market Segmentation
-
By Surgery Type:
- Cardiothoracic: 40%
- Vascular: 25%
- General surgery: 20%
- Others (neurosurgery, gynecologic): 15%
-
Geographies:
- North America: 45%
- Europe: 35%
- Asia-Pacific: 15%
- Rest of world: 5%
Regulatory and Adoption Trends
- Increased adoption in minimally invasive surgeries.
- Growing preference for biosynthetic and biologic hemostatic agents.
- Stringent regulatory pathways in advanced markets prolong approval cycles but also drive product differentiation.
Market Projections
CAGR and Revenue Forecasts
The surgical hemostatic market is expected to grow at a compound annual growth rate (CAGR) of 6.2% from 2023 to 2028.
| Year |
Market Size (USD billion) |
| 2023 |
3.03 |
| 2024 |
3.22 |
| 2025 |
3.43 |
| 2026 |
3.65 |
| 2027 |
3.89 |
| 2028 |
4.14 |
TACHOSIL Revenue Potential
- Current global sales estimated at USD 120-150 million in 2023.
- Market share could reach 4-6% in the hemostatic market within five years, driven by increasing clinical preference and regulatory approvals.
- Focus markets include North America, Europe, and Japan where product approvals are in place.
Growth Drivers
- Rising volume of cardiovascular surgeries.
- Increasing prevalence of coagulopathies.
- Surge in minimally invasive procedures requiring effective hemostats.
- Ongoing expansion into emerging markets with growing healthcare infrastructure.
Challenges and Risks
- Competitive pressure from established brands.
- Limited data beyond initial trials may retard adoption.
- Regulatory delays in emerging regions.
- Cost considerations influencing hospital procurement decisions.
Strategic Outlook
- Partnership or licensing deals with regional distributors could accelerate uptake.
- Investment in post-market studies to bolster clinical evidence.
- Diversification into new surgical applications (e.g., trauma, military).
Key Takeaways
TACHOSIL has a well-established regulatory position mainly in Europe, the US, and Japan, with clinical data supporting its efficacy. The global market for hemostatic agents is expanding, driven by surgical volume increases, especially in cardiothoracic and vascular domains. Future growth depends on gaining market share against competitors, expanding indications, and enhancing clinical evidence.
FAQs
1. What approvals does TACHOSIL have globally?
It has CE Mark (Europe, 2010), FDA 510(k) clearance (USA, 2012), and Japanese approval (2012).
2. How does TACHOSIL compare to other hemostats?
It is collagen-based, with high adhesion and biocompatibility, comparable in effectiveness to gelatin-thrombin products but with distinct adhesive properties.
3. What are the main markets for TACHOSIL?
North America, Europe, and Japan dominate, accounting for approximately 80% of sales.
4. What clinical evidence supports TACHOSIL’s efficacy?
Multiple trials report >90% intraoperative hemostasis success, with a safety profile similar to other biosurgical products.
5. What growth strategies could enhance TACHOSIL’s market presence?
Expanding indications, conducting large-scale RCTs, forging regional partnerships, and penetrating emerging markets.
References:
[1] MarketWatch. (2022). Surgical Hemostats Market Size, Share & Trends.
[2] European Medicines Agency. (2010). CE Mark approval documentation.
[3] U.S. Food and Drug Administration. (2012). 510(k) Summary for TACHOSIL.
[4] Japanese Pharmaceuticals and Medical Devices Agency. (2012). Approval documentation.
